Even though few studies have shown the association of FAS/FASL polymorphisms with susceptibility risk of various cancers, till date there is only one report on its association with CML susceptibility risk worldwide (Edathara et al., 2016). This evidence concerns the gene FASLG and chronic myelogenous leukemia, BCR-ABL1 positive.